Polen Capital Management LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Polen Capital Management LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,223 shares of the company’s stock after purchasing an additional 1,259 shares during the quarter. Polen Capital Management LLC owned 0.05% of Medpace worth $5,390,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. GWN Securities Inc. purchased a new stake in Medpace in the 4th quarter valued at approximately $278,000. Corient Private Wealth LLC boosted its holdings in Medpace by 86.1% in the 4th quarter. Corient Private Wealth LLC now owns 2,380 shares of the company’s stock valued at $791,000 after purchasing an additional 1,101 shares in the last quarter. Natixis Advisors LLC boosted its holdings in Medpace by 27.1% in the 4th quarter. Natixis Advisors LLC now owns 14,287 shares of the company’s stock valued at $4,747,000 after purchasing an additional 3,042 shares in the last quarter. Madison Investment Advisors LLC purchased a new stake in shares of Medpace during the 4th quarter worth approximately $2,308,000. Finally, Balboa Wealth Partners purchased a new stake in shares of Medpace during the 4th quarter worth approximately $201,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of Medpace stock opened at $324.95 on Monday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The company has a market capitalization of $9.90 billion, a P/E ratio of 25.73, a P/E/G ratio of 3.81 and a beta of 1.47. The business has a 50 day moving average price of $340.28 and a 200 day moving average price of $340.84.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.